Northeast Investment Management Sells 321 Shares of Danaher Co. (NYSE:DHR)

Northeast Investment Management cut its stake in shares of Danaher Co. (NYSE:DHR) by 0.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 177,859 shares of the conglomerate’s stock after selling 321 shares during the period. Danaher accounts for approximately 2.1% of Northeast Investment Management’s portfolio, making the stock its 13th largest holding. Northeast Investment Management’s holdings in Danaher were worth $44,438,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Cape Investment Advisory Inc. bought a new position in shares of Danaher in the fourth quarter worth approximately $25,000. Tsfg LLC increased its position in shares of Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher in the second quarter worth approximately $25,000. Redmont Wealth Advisors LLC bought a new position in shares of Danaher in the first quarter worth approximately $30,000. Finally, Richardson Financial Services Inc. bought a new position in shares of Danaher in the fourth quarter worth approximately $42,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Trading Down 1.0 %

DHR stock traded down $2.76 on Wednesday, reaching $266.06. The company’s stock had a trading volume of 1,692,342 shares, compared to its average volume of 2,797,592. The business has a fifty day simple moving average of $259.22 and a two-hundred day simple moving average of $254.78. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The firm has a market cap of $197.07 billion, a PE ratio of 45.09, a PEG ratio of 4.62 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the firm posted $2.05 earnings per share. The firm’s revenue was down 2.9% on a year-over-year basis. As a group, research analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on DHR. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. TD Cowen increased their price target on shares of Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Evercore ISI reduced their price target on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Bank of America increased their price target on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Finally, The Goldman Sachs Group increased their price target on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $278.94.

Insider Buying and Selling

In related news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock valued at $11,042,433 over the last quarter. 11.10% of the stock is owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.